Quarterly report pursuant to Section 13 or 15(d)

Related Party Matters (Details)

v3.21.2
Related Party Matters (Details)
3 Months Ended 4 Months Ended 9 Months Ended
Dec. 19, 2019
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Apr. 30, 2021
agreement
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Related Party Transaction [Line Items]              
Research and development expense   $ 327,731 $ 346,217   $ 1,818,059 $ 1,574,357  
Dr. Avtar Dhillon | Independent Contractor Services Agreement              
Related Party Transaction [Line Items]              
Monthly fee $ 10,000            
Fees incurred under agreement   30,000 $ 31,000   90,000 $ 97,387  
Accrued expense under agreement   20,000     20,000   $ 7,032
Emerald Health Pharmaceuticals | Month To Month Lease Agreement              
Related Party Transaction [Line Items]              
Sublease rent         4,000    
Costs and expenses, related party   8,830     15,453    
Emerald Health Biotechnology Espana, S.L.U. | Collaborative Research Agreement              
Related Party Transaction [Line Items]              
Number of collaborative research agreements | agreement       2      
Initial term of research agreement (years)       1 year      
Termination terms, period following uncured breach (days)       45 days      
Research and development expense   62,940     206,218    
Related party prepaid asset   $ 18,125     $ 18,125    
Emerald Health Biotechnology Espana, S.L.U. | Emerald Health Research, Inc | Collaborative Research Agreement              
Related Party Transaction [Line Items]              
Ownership percentage (percent)       100.00%